Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 7/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.68 |
| ▸ | JUN | P05412 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824235 | 1.00 | CYP1A1 (0.68) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL27680848 | 0.85 | CYP1A2 (0.78) | CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1 | |
| SCHEMBL30831940 | 0.85 | CYP1A2 (0.78) | CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1 | |
| SCHEMBL11874684 | 0.84 | CYP1A1 (0.79) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL11874692 | 0.84 | CYP1A1 (0.79) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL265496 | 0.82 | CYP1A1 (0.70) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL30474601 | 0.82 | CYP1A1 (0.70) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL14224730 | 0.82 | CYP1A1 (0.70) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL7871043 | 0.82 | CYP1A1 (0.70) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL1044979 | 0.81 | CYP1A1 (0.68) | CYP1A1CYP1B1CYP1A2NFE2L2JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-1373261-B1 | CYCLOPROPAHETEROCYCLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-04 | — | — | EP | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR1, NLRP3, NLRP1 | CYP1A1 382/4885CYP1B1 542/4885CYP1A2 911/4885 |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | CXCR1, NLRP3, NLRP1 | CYP1A1 382/4885CYP1B1 542/4885CYP1A2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.